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Abstract
Background: Myasthenia gravis is an autoimmune disease mediated by antibodies against proteins associated with
the postsynaptic membrane of the neuromuscular junction. Several drugs may trigger an exacerbation of the
disease. Melatonin supplements are widely used for the treatment of insomnia as they are well tolerated with few
side effects. The role of melatonin in the immune system and its effects in autoimmune disorders remain uncertain.
Case presentation: We identified three patients in our referral centre from 2014 to 2019 who presented a
worsening within days or weeks of starting melatonin. Two of them stopped the treatment without clinical
improvement in the next week. Increasing dose of corticosteroids did not lead to clinical improvement in the next
month and one of the patients was finally administered intravenous immunoglobulins.
Conclusion: Melatonin may trigger exacerbations of myasthenia gravis, probably due to an upregulation of the
adaptive immune system and an interaction with the corticosteroids and other immunosuppressant treatments. We
consider that melatonin should be administered with caution in these patients.
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Background
Myasthenia gravis (MG) is an autoimmune disease medi-
ated by antibodies against the acetylcholine receptor (anti-
AchR), the muscle-specific kinase (anti-MuSK) or other
proteins associated with the postsynaptic membrane of the
neuromuscular junction. The main clinical manifestations
are muscle weakness and fatigue (which worsens after re-
peated muscular effort) [1]. Symptoms may be exclusively
ocular (ocular MG), with diplopia and/or ptosis, or general-
ized (generalized MG), involving weakness of the limb,
trunk, dysphagia, dysphonia or respiratory insufficiency.
Several drugs, notably sedatives and some antibiotics
may trigger an exacerbation of MG and hence they
should be used with caution, weighing up the risks and
benefits in each patient. Some over-the-counter phar-
macy products may also contain substances that worsen
the symptoms of MG.
Melatonin (N-acetyl-5-methoxytryptamine) is a hor-
mone that is primarily released by the pineal gland and
which is involved in regulating the sleep-wake cycle.
Levels of melatonin decrease with age and this could be
one of the reasons why older adults are more prone to
suffer from insomnia [2].
Because exogenous melatonin binds to the same re-
ceptors as the endogenous form, it is effective as a treat-
ment for insomnia [2–5]. Melatonin supplements are
well tolerated, with few side effects (headache, dizziness,
nausea and drowsiness) and no problems of tolerance.
This is an important advantage over other sedative-
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hypnotic drugs such as antihistamines, antidepressants
and benzodiazepines.
In addition to regulating the sleep-wake cycle, it is be-
coming increasingly clear that melatonin can also have
immunomodulatory effects. There are now several reports
describing the onset or exacerbation of autoimmune dis-
orders after taking supplements containing melatonin or
one of its analogues [6–9]. Here we report the first three
cases of patients with a clinical exacerbation of MG after
administration of melatonin, (Table 1).
Case presentation
We identified three patients in our referral centre from
2014 to 2019 who presented a clinical exacerbation of
myasthenia gravis after starting melatonin treatment.
The study was approved by the Ethics Committee of
Bellvitge University Hospital (PR162/20).
Case 1
The patient was a 49-year-old woman with generalized MG,
negative for both anti-AchR and anti-MuSK antibodies and
with no signs of thymoma on chest computed tomography
(CT) scan. She was being treated with prednisone 10mg/48
h and mycophenolic acid 360mg/12 h, and had been
asymptomatic for MG for over a year (ADL: 0, MGFA: 0,
MG-PIS: PR (https://myasthenia.org/What-is-MG, Appen-
dix in Table 2, Appendix in Table 3 and Appendix in Table
4). Due to persistent insomnia she began taking an over-
the-counter melatonin supplement, 1.95mg/day. A few
weeks later she presented with constant binocular diplopia,
dysphonia and generalized tiredness (ADL: 5), with no other
identifiable triggers. Due to the temporal relationship be-
tween her symptoms and starting the melatonin supplement
she was advised to cease taking it. She did not start
treatment with pyridostigmine due to gastrointestinal inoto-
lerance. As little improvement was initially observed in the
next week, the dose of prednisone was increased to 50mg/
24 h. The patient subsequently showed a progressive im-
provement and recovered her baseline status at five weeks.
Case 2
The patient was an 87-year-old man with generalized MG,
positive for anti-AchR antibodies, without signs of thym-
oma on chest CT scan. The medical history included sur-
gery for glottic carcinoma, with residual dysphagia. His
MG symptoms remained stable for over six months with
prednisone 15mg/48 h (ADL 0, MGFA: I, MG-PIS:
MM1), and subsequently the dose was reduced to 10mg/
48 h due to irritability. With this change the patient
remained stable for six weeks. Due to difficulty falling
asleep he began to take melatonin 1.9mg each night. Two
days later he presented constant ptosis during the day and
increased dysphagia (ADL: 4) without evidence of glottic
carcinoma recurrence. After returning to the initial dose
of prednisone, plus pyridostigmine as needed, his symp-
toms stabilized but did not improve. He was advised to
cease the melatonin, but preferred to continue taking it
due to the positive effect on his insomnia.
Case 3
The patient was a 35-year-old man diagnosed with general-
ized MG, positive for anti-AchR antibodies. Chest CT scan
showed no thymoma, the patient having undergone a
thymectomy (thymus hyperplasia). He was being treated
with pyridostigmine 60mg/4 h, mycophenolic acid 540mg/
day in two divided doses and prednisone 15mg/48 h. With
this treatment his MG symptoms were well controlled for
over a year, and he only presented intermittent diplopia
Table 1 Clinical characteristics of the patients
Patient Patient 1 Patient 2 Patient 3
Age (years) 49 87 35
Type of MG Generalized Generalized Generalized
Antibodies Double seronegative Positive for anti-AchR Positive for anti-AchR
Treatment PDN 10 mg/48 h and
MA 360 mg/12 h
PDN 10 mg/48 h PDN 10 mg/48 h and MA 540 mg/24 h
MGFA prior to taking melatonin 0 I I
MGFA-PIS prior to taking melatonin PR MM1 MM3
ADL score prior to taking melatonin 0 0 2
Melatonin dose 1.95 mg/day 1.9 mg/day 1.95 mg/day
Time from start of melatonin to worsening 3 weeks 2 days 7 days
Deterioration in ADL score 5 4 7
Melatonin ceased Yes No Yes
Treatment received Increased dose of PDN Increased dose of PDN Increased dose of PDN plus IVIG
Time from cessation of melatonin to improvement 5 weeks – 6 weeks
MG myasthenia gravis, anti-AchR antibodies against the acetylcholine receptor, PDN prednisone, MA mycophenolic acid, IVIG intravenous immunoglobulins, MGFA
Myasthenia Gravis Foundation of America Clinical Classification, MGFA-PIS Myasthenia Gravis Foundation of America Post-Intervention Status, PR Pharmacological
Remission, MM Minimal Manifestations, ADL Activities of Daily Living Profile
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during the day (ADL: 2, MGFA I; MGFA-PIS: MM3). After
a period of six months during which he suffered from in-
somnia, he began treatment with doxylamine, with no
worsening of his MG, but this treatment was suspended
due to ineffectiveness. One month after cessation of doxyla-
mine, and due to the persistence of his insomnia, he began
taking an over-the-counter supplement containing mela-
tonin 1.95mg/day. One week later he presented a progres-
sive worsening of his MG, with no other identifiable trigger.
Neurological examination revealed facial muscle weakness,
difficulty chewing and appendicular weakness and fatigabil-
ity (ADL: 7 points). He ceased taking melatonin, but in the
absence of improvement over the next few days the dose of
prednisone was increased to 30mg/24 h. The patient’s ADL
score remained at 6 for the following month and it was
thus decided to administer intravenous immunoglobulins
at a dose of 0.4 g/kg/day for 5 days. Two weeks after this
treatment the patient experienced a marked clinical im-
provement, and at one month he had returned to his base-
line status.
Discussion and conclusions
Melatonin and its agonists are widely used in the treatment
of insomnia, which has a prevalence in the general popula-
tion of 30–50% [10, 11]. In some European countries, mela-
tonin supplements may be purchased over the counter
(without prescription) in pharmacies, provided that the tab-
lets contain less than 2mg of the active substance. Import-
antly, the use of melatonin among the general population
has increased in recent years due to it being indicated as a
treatment for REM sleep disorders [12], jet lag, chronic mi-
graine, cluster headache [13] and chronic pain [14].
Another less well known function of melatonin is as an
immune system regulator, it modulates both the innate
and specific immune response. Here we describe three pa-
tients with MG whose symptoms were well controlled
with a low maintenance dose of corticosteroids (plus, in
two cases, with mycophenolic acid as a steroid-sparing
agent) and who presented a worsening of their condition
within days or weeks of starting melatonin. The fact that
the exacerbation of MG symptoms manifested some days
after starting melatonin suggests a mechanism of action
other than its direct sedative effect, which would have oc-
curred within an hour of taking it [12].
All patients were asked about recent infectious diseases,
increased stress, surgery, changes in their usual treatments
or other supplement intake. Although in Patient 1 there was
no other identifiable trigger, possible triggers were present
in the other two cases: a reduction in the maintenance dose
of prednisone in Patient 2 and prescription of doxylamine in
Patient 3. However, Patient 2 remained stable for six weeks
with the reduced dose of glucocorticoid, while Patient 3
showed no change in symptoms in the month following ces-
sation of doxylamine. By contrast, both patients presented
neurological deterioration several days after beginning to
take a melatonin supplement, hence the suspicion that
melatonin had a role in their clinical exacerbation.
In none of the three patients did an increased dose of
corticosteroids lead to meaningful clinical improvement
in the next month. Patient 1 took five weeks to achieve
symptom remission following cessation of melatonin,
while Patient 3 was administered intravenous immuno-
globulins four weeks after ceasing melatonin because his
daily activities were still limited as a result of the symp-
tom exacerbation. Patient 2 only experienced a worsen-
ing of his ocular symptoms and otherwise remained
stable despite continuing to take the melatonin supple-
ment. This may be because his MG symptoms were pre-
viously well controlled with a low dose of prednisone,
whereas the other two patients (1 and 3) were also re-
ceiving an immunosuppressant, whose action was likely
to have been affected by the introduction of melatonin.
The immunomodulatory effect of melatonin has become
better understood in recent year. On the one hand mela-
tonin seems to downregulate the overreaction of the in-
nate immune response and promotes the adaptive
immune activity. It enhance B lymphocytes production
and stimulates T helper (Th) cell activity [6, 15] that play
an important role in MG pathogenesis. On the other
hand, it also increases the production of proinflammatory
interleukin (IL). IL2 can induce resistance to glucocorti-
coids (both endogenous and exogenous) in Th cells [16]
and may explain why these patients did not respond to an
increased dose of glucocorticoids, when previously they
had done. This effect is likely to persist beyond the plasma
elimination [17] of exogenous melatonin, which would
also account for why these patients did not improve until
several weeks after cessation of melatonin.
The role of melatonin in autoimmune disorders such
as rheumatoid arthritis and Crohn’s disease has previ-
ously been reported [15, 16, 18]. In the literature there
are three case reports of autoimmune hepatitis after
treatment with melatonin: two involved patients with no
prior autoimmune disease [8, 9], while the other was a
patient with primary sclerosing cholangitis and ulcera-
tive colitis whose treatment included mycophenolate
mofetil [7]. The three cases described here are the first
in which melatonin administration was associated with
symptom exacerbation in patients with MG who were
being treated with immunosuppressants.
The use of melatonin in patients with MG, whether
ocular or generalized, may trigger exacerbations of the
disease, probably due to an upregulation of adaptative
immune response and an interaction with treatment in-
volving corticosteroids and other immunosuppressants.
We consider that melatonin should be administered with
caution in patients with MG, especially those who are
being treated with immunosuppressants.
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Appendix 1
Table 2 Activities of Daily Living (ADL) Score range from 0 to 24 points. It was created to assess the impact of MG on activities of
daily living. This scale includes eight functions that are often impaired in MG. It surveys symptom severity, with each response
graded from 0 (normal) to 3 (most severe), (https://myasthenia.org/What-is-MG)
Grade 0 1 2 3
Talking Normal Intermittent slurring or nasal
speech




Chewing Normal Fatigue with solid food Fatigue with soft food Gastric tube
Swallowing Normal Rare episode of choking Frequent choking necessitating
changes in diet
Gastric tube
Breathing Normal Shortness of breath with
exertion
Shortness of breath at rest Ventilator dependence
Impairment of ability to brush teeth
or comb hair
Normal Extra effort, but no rest
periods needed
Rest periods needed Cannot do one of these
functions
Impairment of ability to arise from
chair
Normal Mild, sometimes uses arms Moderate, always uses arms Severe, requires
assistance
Double vision Normal Occurs, but not daily Daily, but not constant Constant
Eyelid droop Normal Occurs, but not daily Daily, but not constant Constant
Appendix 2
Table 3 Myasthenia gravis foundation of America (MGFA) Clinical Classification. The sclae divides MG into 5 classes and several
subclasses to identify subgroups of patients with MG who share distinct clinical features or severity of disease that may indicate
different prognoses or responses to therapy, (https://myasthenia.org/What-is-MG)
Class I: Any ocular muscle weakness; may have weakness of eye closure. All other muscle strength is normal.
Class II: Mild weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
A. IIa. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
B. IIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or both.
Class III: Moderate weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
A. IIIa. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
B. IIIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or
both.
Class IV: Severe weakness affecting muscles other than ocular muscles; may also have ocular muscle weakness of any severity.
A. IVa. Predominantly affecting limb, axial muscles, or both. May also have lesser involvement of oropharyngeal muscles.
B. IVb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May also have lesser or equal involvement of limb, axial muscles, or
both.
Class V: Defined as intubation, with or without mechanical ventilation, except when employed during routine postoperative management. The use
of a feeding tube without intubation places the patient in class IVb.
Appendix 3
Table 4 MGFA Post-intervention Status (MGFA-PIS)
Complete Stable Remission (CSR)
The patient has had no symptoms or signs of MG for at least 1 year and has received no therapy for MG during that time. Isolated weakness of
eyelid closure is accepted.
Pharmacologic Remission (PR)
The same criteria as for CSR except that the patient continues to take some form of therapy for MG. Patients taking cholinesterase inhibitors are
excluded from this category.
Minimal Manifestations (MM)
The patient has no symptoms of functional limitations from MG but has some weakness on examination of some muscles.
MM-0: The patient has received no MG treatment for at least 1 year.
MM-1: The patient continues to receive some form of immunosuppression but no cholinesterase inhibitors or other symptomatic therapy.
MM-2: The patient has received only low-dose cholinesterase inhibitors (< 120mg pyridostigmine/day) for at least 1 year.
MM-3: The patient has received cholinesterase inhibitors or other symptomatic therapy and some form of immunosuppression during the past year.
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